摘要
目的探讨奥氮平治疗阿尔茨海默病患者行为和精神症状的临床疗效和安全性。方法对66例阿尔茨海默病患者予以口服奥氮平治疗，观察6周。于治疗前后采用Alzheimer病行为病理学量表评定入组患者的行为和精神症状。结果入组患者治疗后Alzheimer病行为病理学评定量表评分，除情感障碍因子分无显著变化（P〉0．05）外，总分及其他因子分均显著低于治疗前（P〈0．01）；治疗后偏执与妄想观念、幻觉、行为紊乱、攻击行为及日夜节律紊乱检出率均显著低于治疗前（P〈0．01）；不引起／不加重患者的认知功能损害，不良反应发生率低，程度较轻微。结论奥氮平能显著改善阿尔茨海默病患者的行为和精神症状，有效缓解患者的攻击行为，且不损害认知功能，治疗安全性高，依从性好。
Objective To explore the clinical efficacy and safety ot olanzapine in the treatment of Denavloral and psychological symptoms of Alzheimer^s disease （AD）. Methods Sixty-six AD patients were treated with oral olanzapine for 6 weeks. Behavioral and psychological symptoms were assessed with the Behavioral Pathology in Alzheimer＇ s Disease Rating Sacel （BEHAVE-AD） before and after treatment, the BE- HAVE-AD was used to assess the patients＇ behaviors and psychotic symptoms. Results Except affective disorder （P〉0.05）, the total and other factors＇ scores of the BEHAVE-AD were significantly lower after treament compared with pretreatment （P〈0.01） ; after treatment detection rates of paranoia and delusion al idea, hallucination, conduct disorder, aggressive behavior and loss of diurnal rhythm were significantly lower compared with pretreatment （P〈0.01）; Olanzapine didn＇t cause and aggravate cognitive impairment, its adverse reactions had lower incidences and were mild. Conclusion Olanzapine could notably improve the behavioral and psychological symptoms, relieves aggressive behavior effectively, doesn＇t damage cognitive function and has higher safety and better compliance in AD.
出处
《临床心身疾病杂志》
CAS
2011年第5期409-410,416,共3页
Journal of Clinical Psychosomatic Diseases
